Answers are grounded in this paper and cite their sources.
Background and Aims: Hepatocellular carcinoma (HCC) risk in patients with cirrhosis can be predicted by cross-sectional assessment of biomarkers and/or clinical scores, including the Prognostic Liver Secretome signature (PLSec)-based PAaM score. However, HCC risk may change over time, potentially limiting the accuracy of cross-sectional risk prediction. We aimed to evaluate whether longitudinal changes in HCC risk biomarkers/scores improve upon one-time risk assessment. Approach and Results: In this nested case-control study within the multi-center prospective National Cancer Institute HCC Early Detection Strategy (HEDS) cohort of patients with cirrhosis, we evaluated longitudinal changes in PLSec over 1 or 2 years. Paired baseline and follow-up serum samples were available for 31 cases and 93 controls for 1-year changes, and for 25 cases and 75 controls for 2-year changes. Cross-sectional PLSec scores were higher in cases than in controls at baseline, Year 1, and Year 2 ( p <0.05). The 2-year change in PLSec score (delta-PLSec-Y2) was higher in cases than in controls ( p =0.026; AUROC, 0.65; adjusted odds ratio, 1.47 [95% CI, 1.04–2.15]). In multivariable logistic regression, delta-PLSec-Y2 remained significantly associated with HCC risk ( p =0.041) along with baseline PAaM. Conclusions: Longitudinal assessment of PLSec at a 2-year interval may provide additional information to refine cross-sectional HCC risk assessment, warranting further independent validation, evaluation of longer intervals, and exploration of optimal re-testing frequency.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: